During the COVID-19 crisis, managed care professionals are facing unique challenges to deliver patient care. This resource center is designed to aggregate timely information for AMCP members and stakeholders.
AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
AMCP Submits Comments on PDUFA; AMCP Joins Influenza Antiviral Sign-on Letter; AMCP Joins COVID-19 Antiviral Recommendations Sign-on Letter; President Biden Signs Infrastructure Investment and Jobs Act; President Biden To Nominate Dr. Robert Califf for FDA Commissioner.
Sponsored webinar that discussed what is health equity and why is it emerging as a hot topic now, how do we address participation gaps in clinical trials, how can health plans respond to health disparities, and how can data be used to identify gaps in care and improve health equity.